Sign up to save your podcasts
Or
Share Professor Claire Harrison - Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Professor Claire Harrison - Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era
Go online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have emerged, including those over the use of multiple JAK inhibitor options in patients failing prior targeted therapy or those who present with challenging clinical features at baseline, among others. The answers to these questions will likely define the future of risk-adapted therapy in myelofibrosis and clarify treatment protocols in an era of several JAK inhibitor options. In this activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, experts in oncology and hematology explore the answers to these questions via a unique MasterClass and Case Forum format, designed to offer learners a window into the scientific evidence supporting new JAK inhibitor options in myelofibrosis, while also providing a case-centric illustration of how this science can be applied in daily care. This activity marries expert insight on practice-changing science with recommendations from the therapeutic “masters” and highlights how JAK inhibitor options are making a difference in patient outcomes across the myelofibrosis treatment continuum. Upon completion of this activity, participants should be better able to: Describe molecular and clinical features of myelofibrosis (MF) that are useful for diagnostic and prognostic assessment, Summarize recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of MF, Select individualized, risk-adapted treatment plans for patients with symptomatic or asymptomatic MF, including those failing prior JAK inhibitor therapy.
View all episodes
By PVI, PeerView Institute for Medical Education
5
33 ratings
Go online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have emerged, including those over the use of multiple JAK inhibitor options in patients failing prior targeted therapy or those who present with challenging clinical features at baseline, among others. The answers to these questions will likely define the future of risk-adapted therapy in myelofibrosis and clarify treatment protocols in an era of several JAK inhibitor options. In this activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, experts in oncology and hematology explore the answers to these questions via a unique MasterClass and Case Forum format, designed to offer learners a window into the scientific evidence supporting new JAK inhibitor options in myelofibrosis, while also providing a case-centric illustration of how this science can be applied in daily care. This activity marries expert insight on practice-changing science with recommendations from the therapeutic “masters” and highlights how JAK inhibitor options are making a difference in patient outcomes across the myelofibrosis treatment continuum. Upon completion of this activity, participants should be better able to: Describe molecular and clinical features of myelofibrosis (MF) that are useful for diagnostic and prognostic assessment, Summarize recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of MF, Select individualized, risk-adapted treatment plans for patients with symptomatic or asymptomatic MF, including those failing prior JAK inhibitor therapy.
More shows like PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners